The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
 
Alexander Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Galera Therapeutics; Gilead Sciences; InhibRx; leidos biomedical research; McGivney Global Advisors
Research Funding - Abbvie; Abbvie; adpnp; AstraZeneca; Atara Biotherapeutics; BioNtech; BioNTech SE; BMS; Cellsight Technologies; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Gilead Sciences; Incyte; Incyte; Incyte; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Replimune; Tessa Therapeutics; Threshold Pharmaceuticals; Viracta Therapeutics
 
Christine H. Chung
Consulting or Advisory Role - AVEO; Exelixis; Fulgent Pharma; Genmab; Seagen
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Vaccitech
Research Funding - Adagene (Inst); AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); NCCN/Lilly (Inst); OncoC4 (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
 
Jong Chul Park
No Relationships to Disclose
 
Michael K. Gibson
Honoraria - Astellas Pharma; Coherus Biosciences; Daiichi Sankyo/Lilly; Regeneron
Consulting or Advisory Role - Abbvie; regeneron; UpToDate
Research Funding - Daiichi Sankyo/Lilly (Inst); PapiVax Biotech, Inc. (Inst)
 
Ammar Sukari
Stock and Other Ownership Interests - Bristol-Myers Squibb/Pfizer; Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Francis P. Worden
Honoraria - Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; eisai; Exelixis; Loxo; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Loxo/Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Faye M. Johnson
Honoraria - Emory University; Methodist Hospital
Research Funding - CUE Biopharma (Inst); PIQUR; Puma Biotechnology (Inst); Takeda; Takeda (Inst); Trovagene; Viracta Therapeutics (Inst)
 
Nabil F. Saba
Honoraria - American Journal OF Managed Care; AstraZeneca; Coherus Biosciences; Eisai; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Inovio Pharmaceuticals; Merck; Novartis; Taiho Pharmaceutical; TOSK; vaccinex
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; GlaxoSmithKline; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
Barbara Burtness
Consulting or Advisory Role - Abbvie; ALX Oncology; Arvinas; Coherus Biosciences; CUE Biopharma; Eisai; Genentech/Roche; IO Biotech; Janssen Oncology; Kura Oncology; Macrogenics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Orphagen Pharmaceuticals; Rakuten Medical; Seagen; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); IO Biotech (Inst); Merck; Merck (Inst)
Expert Testimony - Cel-Sci Corporation
 
Ricklie Ann Julian
Consulting or Advisory Role - BioAtla; Jazz Pharmaceuticals
Speakers' Bureau - Jazz Pharmaceuticals
Travel, Accommodations, Expenses - BioAtla
 
Julie E. Bauman
Consulting or Advisory Role - BlueDot; Exelixis
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Lilly (Inst); Moderna Therapeutics (Inst); Novartis (Inst)
 
Robert M. Jotte
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics
 
Tanguy Y. Seiwert
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; BioNTech SE; BostonGene; CUE Biopharma; Eisai; Exelixis; Innate Pharma; IO Biotech; ITeos Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi; Seattle Genetics/Astellas; Surface Oncology; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune; Seagan; Seagan
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Steven Margossian
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Patents, Royalties, Other Intellectual Property - Cue Biopharma
 
Matteo Levisetti
Employment - Cue Biopharma
Leadership - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Cue Biopharma
 
Sara I. Pai
Consulting or Advisory Role - CUE Biopharma; Incendia Pharmaceuticals AB; Merck; MSD Oncology; Sensei Biotherapeutics
Research Funding - Abbvie; AstraZeneca/MedImmune (Inst); CUE Biopharma; Merck (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/MedImmune; Merck